GLOPID-R

Upcoming ISARIC webinar: use of convalescent plasma in patients hospitalised with COVID-19

Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus. Although convalescent plasma has been widely used in patients admitted to hospital with COVID-19, data from randomised controlled trials in this patient group have, until recently, been limited.

Organised by ISARIC, a GloPID-R partner, the webinar on June 10, 2021 aims to:

  • provide up-to-date information from randomised controlled trials on evidence of the effectiveness and safety of convalescent plasma in patients admitted to hospital with COVID-19, and
  • identify key questions for translating the clinical trial evidence on the use of convalescent plasma in patients admitted to hospital with COVID-19 into clinical practice.

Learn more & register

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.